United Therapeutics COO executes 10b5-1 plan, sells stock from trusts
Rhea-AI Filing Summary
United Therapeutics insider activity: Michael Benkowitz, President and COO, exercised stock options and sold the resulting shares on 09/22/2025 under a Rule 10b5-1 trading plan entered into June 3, 2025. The filing shows exercise of 14,625 options at $135.42 and sale of the resulting 14,625 shares at $416.3535, and exercise of 7,875 options at $146.03 with sale of those 7,875 shares at $416.3535. Following the sales, the reported beneficial ownership from the two trusts tied to the reporting person shows 0 shares for the sold lots. The transactions were executed through trusts of which the reporting person is a beneficiary or trustee, and were signed under power of attorney on 09/23/2025.
Positive
- Transactions executed under a Rule 10b5-1 plan dated June 3, 2025, indicating pre-established trading instructions.
- Full disclosure of option exercises, sale prices, and trust relationships, supporting regulatory transparency.
Negative
- Sales reduced reported beneficial ownership to 0 shares for the sold lots held in the two trusts, indicating significant disposition of those trust-held shares.
Insights
TL;DR: Insider exercised options and sold shares under a pre-established 10b5-1 plan, generating proceeds while following a documented trading plan.
The transactions indicate planned option exercises and sales executed on 09/22/2025 under a Rule 10b5-1 plan dated June 3, 2025. The exercises converted options priced at $135.42 and $146.03 into common shares that were then sold at $416.3535 per share. The filing discloses that the shares sold were held in trusts where the reporting person holds beneficiary or trustee roles, and the post-transaction beneficial ownership for those specific lots is reported as zero. For investors and compliance observers, this is a routine, structured liquidity event rather than an ad hoc sale.
TL;DR: Transaction follows a documented trading plan and includes clear disclosures about trust ownership and power of attorney signature.
The Form 4 provides required detail: option exercise dates, exercise prices, number of options exercised, sale prices, and the nature of indirect ownership via trusts. It specifically notes shared or sole investment and voting power in the trusts and that the trades were pursuant to a 10b5-1 plan. The filing is procedurally compliant and transparent about the reporting person’s relationship to the trusts and the use of a power of attorney to file the form.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options | 14,625 | $0.00 | -- |
| Exercise | Stock Options | 7,875 | $0.00 | -- |
| Exercise | Common Stock | 14,625 | $135.42 | $1.98M |
| Sale | Common Stock | 14,625 | $416.3535 | $6.09M |
| Exercise | Common Stock | 7,875 | $146.03 | $1.15M |
| Sale | Common Stock | 7,875 | $416.3535 | $3.28M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
